Kriya Therapeutics, Inc. clinical trials
The registry lists 6 studies whose lead sponsor is Kriya Therapeutics, Inc.. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 6studies on the registry
- 6open to participants now
Get an email when these change. Save the Kriya Therapeutics, Inc. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Pipeline: 1 programme
Each counted once: 1 with a study Kriya Therapeutics, Inc. leads registered in the last two years.
- Phase 2
The 1 programme — sign in to see the list, free: with every programme, filter by condition or phase and sort by first study or primary completion.
“Registry” is the highest phase of Kriya Therapeutics, Inc.’s own registered studies; Kriya Therapeutics, Inc.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.
What it is testing
The drugs Kriya Therapeutics, Inc.’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
All 6 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Open now6100%
Over the years
- 25
- 526
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Kriya Therapeutics, Inc..
- Kriya Therapeutics, Inc.6 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 6 of 6.
- RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal NeuralgiaRecruitingNCT07596485Phase 1/2
- VV-14300 for the Treatment of Type 1 DiabetesRecruitingNCT07831798Phase 1/2
- VV-14299 and VV-14300 for the Treatment of Type 1 DiabetesRecruitingNCT07829302Phase 1/2
- A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)RecruitingNCT07732400Phase 1/2
- A Study of VV-14305 for the Treatment of Thyroid Eye DiseaseRecruitingNCT07404111Phase 1/2
- A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular DegenerationRecruitingNCT06765980Phase 1/2